r DCPH Stock Quote - Deciphera Pharmaceuticals, Inc. Stock Price Today

Deciphera Pharmaceuticals, Inc.

( )
DCPH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen Inc.
CELGCelgene Corporation
GILDGilead Sciences, Inc.
BIIBBiogen Inc.
ALXNAlexion Pharmaceuticals, Inc.
REGNRegeneron Pharmaceuticals, Inc.
VRTXVertex Pharmaceuticals Incorporated
NKTRNektar Therapeutics
AAgilent Technologies, Inc.
ILMNIllumina, Inc.
INCYIncyte Corporation
EXASExact Sciences Corporation
SRPTSarepta Therapeutics, Inc.
BLUEBluebird Bio, Inc.
BMRNBioMarin Pharmaceutical Inc.

Company Profile

Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.